Azitra (NYSEAMERICAN:AZTR) Trading Down 8%

Azitra, Inc. (NYSEAMERICAN:AZTRGet Free Report)’s share price was down 8% during trading on Friday . The stock traded as low as $0.20 and last traded at $0.23. Approximately 2,252,051 shares changed hands during trading, an increase of 252% from the average daily volume of 638,911 shares. The stock had previously closed at $0.25.

Azitra Stock Performance

The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 0.01.

Insider Buying and Selling at Azitra

In other Azitra news, CEO Francisco D. Salva bought 333,300 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were bought at an average price of $0.30 per share, for a total transaction of $99,990.00. Following the transaction, the chief executive officer now directly owns 338,300 shares in the company, valued at $101,490. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have acquired 399,200 shares of company stock worth $115,476 over the last ninety days.

Institutional Investors Weigh In On Azitra

A hedge fund recently raised its stake in Azitra stock. Warberg Asset Management LLC raised its position in Azitra, Inc. (NYSEAMERICAN:AZTRFree Report) by 20.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 35,000 shares of the company’s stock after acquiring an additional 6,000 shares during the quarter. Warberg Asset Management LLC owned approximately 0.29% of Azitra worth $52,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.16% of the company’s stock.

Azitra Company Profile

(Get Free Report)

Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.

See Also

Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.